170 related articles for article (PubMed ID: 11585865)
1. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Zalutsky MR; Zhao XG; Alston KL; Bigner D
J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
[TBL] [Abstract][Full Text] [Related]
2. Labeling Monoclonal Antibody with α-emitting
Vaidyanathan G; Pozzi OR; Choi J; Zhao XG; Murphy S; Zalutsky MR
Cancer Biother Radiopharm; 2020 Sep; 35(7):511-519. PubMed ID: 32109139
[No Abstract] [Full Text] [Related]
3. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
[TBL] [Abstract][Full Text] [Related]
4. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
Reist CJ; Bigner DD; Zalutsky MR
Clin Cancer Res; 1998 Oct; 4(10):2495-502. PubMed ID: 9796983
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
[TBL] [Abstract][Full Text] [Related]
6. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
Pozzi OR; Zalutsky MR
J Nucl Med; 2007 Jul; 48(7):1190-6. PubMed ID: 17574991
[TBL] [Abstract][Full Text] [Related]
7. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
Pozzi OR; Zalutsky MR
J Nucl Med; 2005 Aug; 46(8):1393-400. PubMed ID: 16085599
[TBL] [Abstract][Full Text] [Related]
8. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
[TBL] [Abstract][Full Text] [Related]
9. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
Pozzi OR; Zalutsky MR
J Nucl Med; 2005 Apr; 46(4):700-6. PubMed ID: 15809494
[TBL] [Abstract][Full Text] [Related]
10. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
[TBL] [Abstract][Full Text] [Related]
11. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Larsen RH; Akabani G; Welsh P; Zalutsky MR
Radiat Res; 1998 Feb; 149(2):155-62. PubMed ID: 9457895
[TBL] [Abstract][Full Text] [Related]
12. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
13. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
Boskovitz A; Akabani GH; Pegram CN; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Apr; 31(3):345-55. PubMed ID: 15028247
[TBL] [Abstract][Full Text] [Related]
14. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
Salako QA; O'Donnell RT; DeNardo SJ
J Nucl Med; 1998 Apr; 39(4):667-70. PubMed ID: 9544679
[TBL] [Abstract][Full Text] [Related]
15. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
Yao Z; Garmestani K; Wong KJ; Park LS; Dadachova E; Yordanov A; Waldmann TA; Eckelman WC; Paik CH; Carrasquillo JA
J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
[TBL] [Abstract][Full Text] [Related]
16. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
[TBL] [Abstract][Full Text] [Related]
18. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
[TBL] [Abstract][Full Text] [Related]
20. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
